Health Care

Explore how insider trading and new equity awards at Establishment Labs Holdings impact investor confidence and future growth prospects.

Seres Therapeutics CEO exercises 6,500‑share option, signaling confidence in its microbiome platform and upcoming pipeline developments.

Insider sales by TEMPUS AI’s CEO signal potential shifts in confidence, raising questions for investors amid high‑growth, volatile stock trends.

IMMUNOVANT COO’s July 8 sell‑to‑cover of 1,930 shares reveals routine tax‑cover activity, not a confidence shift—insider holdings stay high.

United Therapeutics insider trades reveal strategic capital rebalancing—Malcolm Jan’s modest buys vs. CEO Rothblatt’s 10(b)(5)(1) sales—offering investors insight into potential pipeline shifts while fundamentals stay strong.

TruBridge’s final sell‑off by Pinetree Capital at $26.25 per share seals its merger into IKS Health, ending an era of independent growth and signaling new opportunities for investors in the healthcare‑tech consolidation wave.

Insight into Perrigo’s recent insider trades shows steady confidence, modest share buying, and neutral market impact—no looming shifts.

Bank of America’s small stake in Bluejay Diagnostics signals institutional confidence, while insider buying suggests management sees hidden value—what it means for investors.

CEO insider activity shows CFO Guarita’s 141,376 RSUs reflect confidence in Perrigo’s rebound—an insider signal for investors to watch the 2027 vesting.

EVP & CSO Lennox Abigail’s July RSU purchase shows Perrigo leadership’s confidence, boosting long‑term upside and reinforcing investor trust.